Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases by Licarete, Emilia et al.
RESEARCH ARTICLE Open Access
Prevalence of collagen VII-specific autoantibodies
in patients with autoimmune and inflammatory
diseases
Emilia Licarete
1,2, Susanne Ganz
1, Martin J Recknagel
3, Giovanni Di Zenzo
4, Takashi Hashimoto
5, Michael Hertl
6,
Giovanna Zambruno
4, Gheorghe Hundorfean
7, Jonas Mudter
7, Markus F Neurath
7, Leena Bruckner-Tuderman
1,8
and Cassian Sitaru
1,8*
Abstract
Background: Autoimmunity to collagen VII is typically associated with the skin blistering disease epidermolysis
bullosa acquisita (EBA), but also occurs occasionally in patients with systemic lupus erythematosus or inflammatory
bowel disease. The aim of our present study was to develop an accurate immunoassay for assessing the presence
of autoantibodies against collagen VII in large cohorts of patients and healthy donors.
Methods: Based on in silico antigenic analysis and previous wetlab epitope mapping data, we designed a chimeric
collagen VII construct containing all collagen VII epitopes with higher antigenicity. ELISA was performed with sera
from patients with EBA (n = 50), Crohn’s disease (CD, n = 50), ulcerative colitis (UC, n = 50), bullous pemphigoid
(BP, n = 76), and pemphigus vulgaris (PV, n = 42) and healthy donors (n = 245).
Results: By ELISA, the receiver operating characteristics analysis yielded an area under the curve of 0.98 (95% CI:
0.9638-1.005), allowing to set the cut-off at 0.32 OD at a calculated specificity of 98% and a sensitivity of 94%.
Running the optimized test showed that serum IgG autoantibodies from 47 EBA (94%; 95% CI: 87.41%-100%), 2 CD
(4%; 95% CI: 0%-9.43%), 8 UC (16%; 95% CI: 5.8%-26%), 2 BP (2.63%; 95% CI: 0%-6.23%), and 4 PV (9.52%; 95% CI:
0%-18.4%) patients as well as from 4 (1.63%; 95% CI: 0%-3.21%) healthy donors reacted with the chimeric protein.
Further analysis revealed that in 34%, 37%, 16% and 100% of sera autoantibodies of IgG1, IgG2, IgG3, and IgG4
isotype, respectively, recognized the recombinant autoantigen.
Conclusions: Using a chimeric protein, we developed a new sensitive and specific ELISA to detect collagen
specific antibodies. Our results show a low prevalence of collagen VII-specific autoantibodies in inflammatory bowel
disease, pemphigus and bullous pemphigoid. Furthermore, we show that the autoimmune response against
collagen VII is dominated by IgG4 autoantibodies. The new immunoassay should prove a useful tool for clinical
and translational research and should improve the routine diagnosis and disease monitoring in diseases associated
with collagen VII-specific autoimmunity.
Background
An immune response against collagen VII is typically asso-
ciated with epidermolysis bullosa acquisita (EBA) and bul-
lous systemic lupus erythematosus, but may occur in
other conditions, including inflammatory bowel disease
(IBD) and dystrophic epidermolysis bullosa [1,2]. EBA is
an acquired subepidermal blistering disease of the skin
and mucous membranes associated with an autoimmune
response to collagen VII [3,4]. EBA is characterized by
bound and circulating IgG autoantibodies which label the
dermal side of split skin by direct and indirect immuno-
fluorescence (IF) microscopy, respectively [5-7]. Accumu-
lating clinical and experimental evidence demonstrates
that collagen VII-specific IgG autoantibodies are patho-
genic. Transient skin blistering was reported in a newborn
from a mother with EBA showing the transplacental
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any medium, provided the original work is properly cited.transfer of pathogenic autoantibodies [8]. IgG autoantibo-
dies from EBA patients induced dermal-epidermal separa-
tion in frozen sections of normal human skin when co-
incubated with granulocytes from healthy donors [9].
Further in vivo work showed that the passive transfer of
collagen VII-specific antibodies into mice induced subepi-
dermal blisters [10]. Immunization with autologous col-
lagen VII induces a T cell-dependent autoimmune
response and subepidermal blisters in mice [11-13].
Collagen VII, the main structural component of the
anchoring fibrils, is a 290 kDa protein composed of three
identical a chains, each consisting of a central collagenase
sensitive triple helical portion flanked by a 145 kDa
N-terminal (NC1) and a 34 kDa C-terminal (NC2) non-col-
lagenous domains [14,15]. Two molecules of collagen VII
associate through a small overlap of the C-terminal NC2
domain resulting in the dimer form present in anchoring
fibrils. In the extracellular space, large part of the NC2
domain is proteolytically removed by bone morphogenetic
protein 1 (BMP-1), an enzyme with procollagen C-protei-
nase activity. In spite of this proteolytic cleavage a small
peptide of NC2 domain consisting of 41 aminoacids still
reside in the dermis, below the lamina densa [16-18]. Epi-
tope mapping studies revealed that the major epitopes
recognized by EBA autoantibodies reside within the NC1
domain of native collagen VII [19,20]. In addition to very
few cases showing reactivity to the triple helical domain of
collagen VII, further important epitopes of EBA autoanti-
bodies have been more recently mapped to the NC2
domain [21,22]. The laboratory diagnosis of EBA relies on
several laboratory tests, including detection of tissue-bound
autoantibodies by direct IF microscopy and demonstration
of serum autoantibody binding to the dermal side of the 1
M salt-split skin by indirect IF microscopy. The definitive
diagnosis of EBA requires characterization of the molecular
specificity of autoantibodies [1]. Autoantibodies against col-
lagen VII are commonly detected by immunoblotting and/
or ELISA using recombinant proteins [1]. While collagen
VII-specific autoantibodies are present in virtually all EBA
patients, their exact prevalence in patients with IBD or
other autoimmune bullous diseases is still controversial
[23,24] or unknown, respectively.
For detection of collagen VII-specific IgG autoantibo-
dies by ELISA, immunoassays using recombinant forms
of the NC1 domain or the full-length molecule have been
developed [22,25-27]. Based on B cell epitope in silico
prediction and wetlab mapping studies, a recombinant
form of collagen VII containing both the NC1 and NC2
domains as well as the hinge region would allow a most
sensitive detection of anti-collagen VII antibodies in
patients. In addition, expression of a lower molecular
mass non-collagenous protein should allow for better
protein yields compared with the expression of the full-
length collagenous molecule. Therefore, in the present
study, we have developed an immunoassay for the detec-
tion of collagen VII-specific autoantibodies using a chi-
meric recombinant fusion protein composed of both non
collagenous domains and the hinge region of collagen
VII. This protein, expressed in stably transfected HEK-
293 cells to ensure optimal posttranslational modifica-
tions, contains all putative epitopes of collagen VII in
equimolar amounts and was utilized to develop a sensi-
tive ELISA for the detection in the same assay of EBA
autoantibodies. Using this immunoassay the prevalence
of collagen VII-specific autoantibodies and their IgG sub-
class was characterized in large cohorts of patients with
IBD, pemphigus vulgaris (PV) and bullous pemphigoid
(BP) as well as healthy donors.
Methods
Human sera
Serum samples were obtained from patients with EBA
(n = 50), Crohn’s disease (CD; n = 50), ulcerative colitis
(UC; n = 50), BP (n = 76), and PV (n = 42) before initia-
tion of treatment and healthy donors (n = 245). EBA and
BP patients were characterized by: (a) subepidermal skin
blisters, (b) linear IgA or IgG deposits along the dermal-
epidermal junction detected by direct IF microscopy, and
(c) circulating IgG autoantibodies binding to the epidermal
(BP) or dermal (EBA) side of the salt-split skin as revealed
by IF microscopy. PV was diagnosed in patients presenting
(a) intraepidermal skin blisters and mucosal or mucocuta-
neous involvement, (b) intercellular IgG deposits within
the epidermis detected by direct immunofluorescence
(DIF) microscopy, (c) Serum IgG autoantibodies binding
to the epithelium of monkey esophagus with an intercellu-
lar pattern by IF microscopy, and (d) IgG autoantibodies
against desmoglein 3 by ELISA. Sera from patients with a
moderate or severe UC or CD were included. The patients
were selected within the IBD section of the Medical Clinic
I Erlangen, University of Erlangen-Nuremberg, having a
confirmed diagnosis for an IBD entity based on the con-
sensus evidence-based clinical, endoscopical and histo-
pathological criteria [28]. The study was approved by the
Ethics Committee of the Medical Faculty of the University
of Freiburg, Germany (Institutional Board Projects no
318/07, 425/08 and 278/11). We obtained informed con-
sent from patients whose material was used in the study,
in adherence to the Helsinki Principles.
Cell culture
Transfected Flp-In HEK 293 T cells (Flp-In™-293, Invitro-
gen) were cultured in DMEM medium, with phenol red
(Lonza) supplemented with 10% FCS, L-glutamine, penicil-
lin, streptomycin (all from Biochrome). When cells reached
70% confluence, complete growth medium was replaced
with serum free medium supplemented with 100 μg/ml of
vitamin C. After 48 hours, cell culture medium was
Licarete et al. BMC Immunology 2012, 13:16
http://www.biomedcentral.com/1471-2172/13/16
Page 2 of 10collected, cleared by centrifugation at 3200 × g for 7 min at
4°C and 5 mM EDTA and 1 mM PMSF were added. The
supernatant was stored at -20°C until used.
Generation of recombinant noncollagenous domains of
human collagen VII
cDNA sequences corresponding to the non-collagenous
domains of human collagen VII (NC1, NC2) were
obtained by polymerase chain reaction (PCR) amplification
on 8xHis tagged full length collagen VII sequence (kind
gift from A Fritsch), previously cloned into prokaryotic
vector pcDNA3.1 Zeo(-), Invitrogen [29]. Primers for PCR
were synthesized by Eurofins MWG (Ebersberg, Germany;
Table 1). Restriction sites for EcoRI and HindIII were
introduced by primers (Table 1). Briefly, pcDNA3.1hcol7
vector containing the full length sequence of human col-
lagen VII was digested with EcoRI and AgeI restriction
enzymes. The digested vector containing the sequence
spanning aminoacids 1-443 was ligated with the PCR frag-
ment overlapping the restriction site for AgeI within col-
lagen VII sequence resulting in the recombinant vector
pcDNA3.1hCol7NC1 containing the entire sequence of
NC1 domain of collagen VII spanning the aminoacids
1-1278. The PCR product corresponding to the NC2 frag-
ment was digested with EcoRI and HindIII restriction
enzymes and ligated into pcDNA3.1hCol7NC1 vector
digested with the same enzyme resulting in the recombi-
nant vector pcDNA3.1hCol7NC1-NC2 with the sequence
spanning the aminoacids 1-1278 and 2776-2944. Subse-
quently, the recombinant fragment (NC1-NC2) was sub-
cloned into the pcDNA5FRT vector with CMV promoter
using NheI and HindIII restriction enzymes resulting
pcDNA5FRThcol7NC1-NC2 recombinant vector. To
obtain the recombinant protein containing NC1, hinge
region and NC2 domains of type VII collagen the nucleo-
tide sequence coding the hinge region and NC2 domain,
flanked by the restriction sites for EcoRI and Hind III, was
synthesized by GenScript in pUC57 vector. Further,
the sequence was cut out with EcoRI and HindIII restric-
tion enzymes and ligated into the pcDNA5FRT NC1-NC2
vector digested with the same enzymes resulting
pcDNA5FRThcol7NC1-H-NC2 recombinant vector con-
taining the sequence spanning the aminoacids 1-1278,
1940-1979 and 2776-2944. Correct DNA sequences of all
vectors were confirmed by direct secquencing. Flp-in
Hek293 T host cells were transfected with 5 μgo f
pcDNA5FRThCol7NC1-NC2/pcDNA5FRThCol7NC1-H-
NC2 and 2.5 μg of pOG44 vectors in lipofectamine2000
(Invitrogen). Transfected cells expressing the desired pro-
teins were selected under 200 μg/ml hygromicine (Roth).
Proteins were precipitated from the culture medium with
50% ammonium sulphate for 4 h at 4°C and collected by
centrifugation at 27000 × g for 45 minutes at 4°C. The
proteins were resuspended in cold PBS, dyalised overnight
against PBS and purified by metallochelate affinity chro-
matography using nickel nitrilotriacetic acid coupled with
agarose (Ni-NTA, Qiagen, Germany). Purified proteins
were separated by SDS PAGE on 8% gels under reducing
conditions and transferred on nitrocellulose membrane.
Membrane strips were incubated with 1000-fold diluted
monoclonal antibody specific for human collagen VII
(clone LH 7.2; Chemicon International, Germany) and
reactivity was detected with secondary, HRP-conjugated
goat anti-mouse IgG antibodies (Abcam).
Enzyme-linked immunosorbent assays
ELISA was developed and performed using previously
established protocols with modification [30,31]. Briefly, 96-
well microtiter plates (Greiner Bio-One, Germany) were
coated with 500 ng/well of recombinant His-hCVII-NC1-
NC2 and an equimolar amount of His-hCVII-NC1-H-NC2
in 0.1 M bicarbonate buffer (pH 9.6), overnight at 4°C.
Next day the plates were washed with 0.05% Tween20-PBS
(w/v) and blocked 1 h with 1% BSA-PBS (w/v) followed by
incubation with 1:100 diluted sera in 1% BSA-0.05%
Tween20-PBS (w/v) for 1 h. Bound antibodies were
detected by 1 hour incubation with a mixture of 2000-fold
diluted biotin conjugated mouse antibodies recognizing the
four human IgG subclasses (Invitrogen) and subsequently
with horseradish-peroxidase conjugated Streptavidin (Dia-
nova) diluted 1:250. After washing, color reaction was
developed by addition of orthophenylene diamine substrate
(Dako). Reaction was stopped after 10 minutes with 0.5 M
sulphuric acid solution. All steps were carried out at room
temperature. The optical density (OD) was read at 492 nm
using an automated spectrophotometer (Sirius HT-TRF,
MWG). Each serum was tested in triplicate. The cut-off for
positivity was validated and optimized by receiver-operat-
ing characteristics (ROC) analysis as described below. The
accuracy of the assay was expressed as sensitivity = true
positive/(true positive + false negative) and specificity =
true negative/(true negative + false positive).
SDS-PAGE and immunoblot analysis
Immunoblotting with recombinant proteins was per-
formed as described with minor modification [31]. Briefly,
preparations of recombinant His-hCVII-NC1-NC2 and
His-hCVII-NC1-H-NC2 proteins were separated by SDS-
Table 1 Primer sequences for PCR amplification of col7a1
cDNA fragments
Fragment Size (bp) Primer sequences (5’-3’)
NC1 2573 FP: GATCCTGGGCCCCACATCCATCCTC
RP: GATCGAATTCGCCCGGGAGGCCAGGGTCG
NC2 524 FP: GATCGAATTCGGCGAGAAGGGAGAAGCTGC
RP: GATCAAGCTTTCAGTCCTGGGCAGTACCTGT
FP forward primer, RP reverse primer
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followed by transfer onto nitrocellulose (Whatman/Pro-
tran BA85). Membrane strips were incubated with
100-fold diluted EBA and normal human sera. Reactivity
was visualized with secondary, HRP-conjugated goat anti-
human IgG antibodies (Abcam) and diaminobenzidine
(Merck).
Indirect immunofluorescence
Serum IgG autoantibodies were detected by IF following
published protocols [31]. Briefly, frozen sections of salt-
split healthy human skin were incubated in a first step
with serially diluted sera. IgG antibodies bound at the der-
mal side were visualized with 100-fold diluted, Alexa
Fluor488-labelled polyclonal goat anti-human IgG anti-
body (Invitrogen).
In silico and statistical analysis
Linear and conformational epitopes on collagen VII were
analyzed in silico using software available at 3 different web
servers. BepiPred predicts the location of linear B-cell epi-
topes using a combination of a hidden Markov model and
a propensity scale method protocol http://www.cbs.dtu.dk/
services/BepiPred/[32]. CBTOPE predicts conformational
B-cell epitope of an antigen from its amino acid sequence
(http://www.imtech.res.in/raghava/cbtope/) [33]. The Pre-
dictor component of Epitope Toolkit (EpiT; http://ailab.cs.
iastate.edu/bcpreds/) was used to predict flexible length lin-
ear B-cell epitopes by the FBCPred algorythm [34]. A ROC
curve allows for exploring the relationship between the
sensitivity and specificity of the ELISA for a variety of dif-
ferent cut-off points, thus allowing the determination of an
optimal cut-off point for positivity. Therefore, to determine
the cut-off value for the ELISA using recombinant forms of
type VII collagen, we performed a ROC analysis by plotting
on the X-axis the 1 - specificity (the false positive rate) and
on the Y-axis the sensitivity (the true positive rate). Statisti-
cal analyses were performed using the GraphPad Prism sta-
tistical package (v5; GraphPad Software, San Diego, CA).
Statistical significance was calculated using the non-
parametric Mann-Whitney-U test and correlations were
analyzed by the Spearman’s rank correlation test; p < 0.05
was considered significant.
Results
In silico prediction of B cell epitope
Wet lab epitope mapping studies using different recom-
binant fragments of collagen VII showed that the epi-
topes targeted by autoantibodies are localized within the
NC1, NC2 and, possibly, the hinge region of the antigen.
To further our understanding about the distribution of B
cell epitopes on collagen VII, we applied in silico analysis
of both linear and conformational epitopes using differ-
ent algorithms. The results revealed that NC1 and NC2
d o m a i n sa sw e l la st h eh i n g er e g i o nw i t h i nt h et r i p l e
helix of collagen VII contain more antigenic sites com-
pared with its collagenous domain (Figure 1, Additional
file 1: Table S1).
Generation of the recombinant forms of the autoantigen
The recombinant proteins were expressed in mammalian
cells and purified by metallochelate affinity chromatogra-
phy. When separated by SDS-PAGE, the recombinant col-
lagen VII forms containing the NC1 fused with the NC2
domain (His-hCVII-NC1-NC2) as well as the hinge region
(His-hCVII-NC1-H-NC2), migrated consistently with their
calculated molecular masses of 153 kDa (Figure 2b, lane 2)
and 158 kDa (Figure 2b, lane 3), respectively. A monoclo-
nal antibody specific for the NC1 domain of collagen VII
recognized both recombinant forms by immunoblot analy-
sis (Figure 2c, lanes 1 and 2).
Immunoreactivity of recombinant collagen VII with EBA
autoantibodies
The immunoreactivity of the newly expressed recombi-
nant chimeric forms of collagen VII was analyzed by
immunoblotting using sera from reference EBA patients
and healthy donors. Representatives examples are shown
in Figure 3. IgG autoantibodies from EBA patients’ sera
(n = 5) recognized the recombinant forms His-hCVII-
NC1-NC2 (Figure 3, lanes 1-3) and His-hCVII-NC1-H-
NC2 (Figure 3, lanes 5-7) of collagen VII. Normal human
sera (n = 2) did not react with these recombinant forms of
collagen VII (Figure 3, lanes 4 and 8).
Figure 1 In silico analysis of B cell epitopes on human collagen
VII. Linear and conformational antigenic determinants of collagen
VII were analyzed in silico using BepiPred (http://www.cbs.dtu.dk/
services/BepiPred/), CBTOPE (http://www.imtech.res.in/raghava/
cbtope) and the Predictor component of Epitope Toolkit (EpiT;
http://ailab.cs.iastate.edu/bcpreds/). The antigenic scores are plotted
for the entire sequence of human collagen VII. The different regions
of the autoantigen, including its non-collagenous (NC) 1 and 2
domains as well as the triple helical (TH) and hinge regions are
shown in the lower part of the figure.
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The working conditions, including antigen amount/well,
dilution of sera and secondary antibodies have been defined
by an initial chessboard titration (data not shown). To
determine the cut-off value of the newly established immu-
noassay, we performed a ROC analysis of the ELISA read-
ings with sera from 50 EBA patients and 160 healthy
donors for the ELISA results obtained with both His-
hCVII-NC1-NC2 and His-hCVII-NC1-H-NC2. The area
under the curve (AUC) was 0.980 (95% CI.: 95%-100%) and
0.984 (95% CI.: 96%-100%) for His-hCVII-NC1-NC2 and
His-hCVII-NC1-H-NC2, respectively (Figure 4). Based on a
calculated specificity of 97.50% and a sensitivity of 92%
(His-hCVII-NC1-NC2) and 94% (His-hCVII-NC1-H-NC2)
the cut-off was set at 0.425 and 0.322 OD reading units for
His-hCVII-NC1-NC2 and His-hCVII-NC1-H-NC2,
respectively.
Figure 2 Recombinant forms of collagen VII used in this study.
(a) Schematic representation of human collagen VII consisting of a
central collagenous domain flanked by a large, 145 kDa N-terminal
non-collagenous domain and a smaller, 30 kDa non-collagen
domain at its C-terminus. The collagenous domain is interrupted by
a 39 amino acid non-collagenous hinge region. The recombinant
forms of collagen VII generated in this study are two N-terminally
8xhistidine tagged chimeric proteins termed His-hCVII-NC1-NC2 and
His-hCVII-NC1-H-NC2 corresponding to the fused NC1 and NC2
domains (aa 1-1278, 2776-2944) and to the fused NC1, hinge and
NC2 regions (1-1278, 1940-1979, 2776-2944) of the antigen,
respectively. (b) Sodium dodecylsulfate-polyacrylamide gel
electrophoresis of the purified recombinant His-hCVII-NC1-NC2 and
His-hCVII-NC1-H-NC2 proteins shows their migration at around 153
(lane 2) and 158 kDa (lane 3), respectively. Weight markers of 200,
116, 97, 66 and 45 kDa are shown in lane 1. (c) Immunoblot
analysis of the two recombinant proteins His-hCVII-NC1-NC2 (lanes 1
and 4) and His-hCVII-NC1-H-NC2 (lanes 2 and 5) as well as a
recombinant form of collagen XVII [47] (lanes 3 and 6) using a
monoclonal antibody specific to the NC1 domain of collagen VII
(clone LH7.2; lanes 1-3) and a monoclonal antibody specific to
soluble ectodomain of collagen XVII [47] (lanes 4-6).
Figure 3 Immunoreactivity of epidermolysis bullosa acquisita
(EBA) autoantibodies with the recombinant forms of collagen
VII. Purified, recombinant His-hCVII-NC1-NC2 (lanes 1-4) and His-
hCVII-NC1-H-NC2 (lanes 5-8) were electrophoretically separated by
8% SDS-PAGE, transferred to nitrocellulose and immunoblotted with
EBA patient’s sera (lanes 1-3 and 5-7) and normal human sera (NHS)
(lanes 4 and 8).
Figure 4 Receiver-operating-characteristic (ROC) curve.A U C ,
area under the curve. Test performed with sera from patients with
epidermolysis bullosa acquisita (n = 50) and controls (n = 160).
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forms of collagen VII allows for a sensitive and specific
detection of antigen-specific autoantibodies
Applying the cut-off value of 0.322 defined by ROC analy-
sis for the newly developed ELISA showed that 47 EBA
(94%; 95% CI: 87%-100%; n = 50), 2 CD (4%; 95% CI: 0%-
9.43%; n = 50), 8 UC (16%; 95% CI: 5.8%-26%; n = 50), 2
BP (2.63%; 95% CI: 0%-6.23%; n = 76), 4 PV (9.52%; 95%
CI: 0%-18.4%; n = 42) patients and 4 of the healthy donors
(1.63%; 95% CI: 0%-3.21%; n = 245) showed IgG reactivity
against the chimeric NC1-hinge-NC2-hCVII protein
(Figure 5). Therefore, a sensitivity and a specificity of 94%
(95% CI: 83.4%-98.75%) and 98%(95% CI: 94%-100%),
respectively, were calculated for the ELISA detecting col-
lagen VII-specific IgG autoantibodies in patients with
EBA. The area under the curve (AUC) was 0.984 (95% CI:
96.3%-100%) indicating an excellent discriminatory power.
The accuracy of the ELISA using only the NC1-NC2
domains of collagen VII was only slightly lower as demon-
strated by a sensitivity of 92% (95% CI: 80.7%-97.7%) and a
specificity of 97.50% (95% CI: 93.7%-99.3%) with an AUC
of 0.980 (data not shown). The immunoassays using the 2
recombinant forms of collagen VII correlated well regard-
ing their capacity to detect specific autoantibodies
(r = 0.95; p < 0.0001).
IgG levels by hCVII ELISA correlate with the IgG reactivity
against the dermal-epidermal junction by IF microscopy
The indirect IF microscopy on salt-split skin is a standard
diagnostic and monitoring tool in autoimmune bullous
diseases. To further characterize the suitability of the
newly developed ELISA for diagnosis of diseases asso-
ciated with autoimmunity against collagen VII, we corre-
lated the IgG levels by ELISA with the end-point titers by
IF microscopy on salt-split skin in sera from patients
with EBA (n = 9). When the IgG levels of collagen VII-
specific IgG autoantibodies were plotted against the IgG
titers measured by indirect IF microscopy, a positive cor-
relation (r = 0.73; p < 0.05) was obtained. Interestingly,
all sera from patients with BP (n = 2), PV (n = 4), CD
(n = 2) and UC (n = 8) as well as from healthy donors
(n = 4), which showed low levels of IgG autoantibodies
against collagen VII by ELISA, did not show binding to
t h ed e r m a ls i d eb yi n d i r e c tI Fm i c r o s c o p yo ns a l t - s p l i t
skin.
Levels of autoantibodies against collagen VII do not
correlate with inflammation markers in inflammatory
bowel disease
C-reactive protein (CRP) is routinely used as marker of
disease activity in patients with IBD, especially in CD. To
address a possible direct role of collagen VII-specific auto-
antibodies in pathogenesis of IBD, the ELISA levels of
autoantibodies were correlated with the CRP values of the
patients at the time of blood collection. The calculated
correlation coefficients were r = 0.135 (p = 0.356) and r =
-0.174 (p = 0.231) for UC and CD patients, respectively.
IgG4 autoantibodies dominate the autoimmune response
against collagen VII
The IgG subclass of collagen VII-specific autoantibodies in
patients’ sera was analyzed by ELISA using recombinant
His-hCVII-NC1-H-NC2 substrate. In 34%, 37%, 16% and
100% of sera autoantibodies of IgG1, IgG2, IgG3, and
IgG4 isotype recognized the recombinant autoantigen
(Figure 6). By correlating the results obtained for the IgG
subclasses with the values obtained by the standard assay,
correlation coefficients of r = -0.07 (p = 0.8), r = 0.17 (p >
0.1), r = 0.24 (p > 0.1) and r = 0.727 (p < 0.001) resulted
for the detection of IgG1, IgG2, IgG3 and IgG4,
respectively.
Discussion
Autoimmune phenomena were observed in the develop-
ment of both cellular and humoral responses. In fact,
there may be significant overlap between the autoreactive
and protective antibodies since polyreactive antibodies
represent a substantial part of the normal repertoire. Anti-
bodies against specific self-antigens are typically associated
with systemic or organ-specific autoimmune diseases, but
may be also found in neoplastic diseases and even in
healthy subjects. EBA is a prototypical organ-specific auto-
immune disease affecting the skin and the mucous mem-
branes associated with autoantibodies against collagen VII
[1]. The blister-inducing potential of collagen VII-specific
Figure 5 ELISA reactivity of human sera with the recombinant
NC1-hinge-NC2 noncollagenous domains of collagen VII. Scatter
plots represent optical density measurements of serum reactivity of
epidermolysis bullosa acquisita (EBA), bullous pemphigoid (BP),
pemphigus vulgaris (PV), Crohn’s disease (CD), ulcerative colitis (UC)
patients and healthy donors (NHS) with the purified recombinant
chimeric collagen VII. (His-hCVII-NC1-H-NC2). The cut-off of the assay
is represented by a dotted line.
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animal models [13]. Autoimmunity against collagen VII
has been described in IBD, which may be clinically asso-
ciated with EBA [2]. Interestingly, collagen VII-specific
autoantibodies are present in IBD patients, which do not
show blistering skin disease [2]. The aim of the present
study, was to analyze collagen VII-specific autoantibodies,
including IgG subclasses in large groups of healthy blood
donors or patients with autoimmune blistering diseases.
The rapid and accurate routine diagnosis of most
autoimmune diseases relies on the detection of autoanti-
bodies with known molecular specificity. Several immu-
noassays have been developed so far for the detection of
autoantibodies against collagen VII (Table 2) [22,25-27].
To further improve the detection of collagen VII-speci-
fic autoantibodies, in the present study we have gener-
ated a chimeric antigen substrate containing virtually all
autoepitopes, which have been reported in previous epi-
tope mapping studies in patients.
Wet lab epitope mapping studies and our present in
silico analysis have shown that the epitopes targeted by
autoantibodies are localized within the NC1, NC2 and
most probably the hinge region of the antigen [19-22].
Therefore, for measuring autoantibodies against collagen
VII we have generated a chimeric protein containing all
putative epitope-bearing regions of collagen VII, including
its NC1 and NC2 domains and the hinge fragment. The
chimeric protein, which was produced in a human cell
line to ensure optimal posttranslational modifications,
shows an increased yield and is more stable compared
with the full-length collagen while containing all the epi-
topes/regions in one copy per molecule. Thus, its use as a
substrate does not require preadsorption against bacterial
proteins and ensures strict equimolar concentration of the
NC1, NC2 and hinge regions.
Interestingly, our in silico analysis predicted the exis-
tence of both linear and conformational epitopes. Since
immunoblotting is not quantitative and uses denatured
antigen, to measure autoantibodies against both linear
and conformational epitopes on collagen VII, we have
used ELISA.
Possible isolated reactivity against hinge was reported
so far only in 3 children with EBA [21] and was appar-
ently present in our relatively large cohort of adult
patients only in one patient. This resulted in a slightly
lower specificity of the ELISA using the fused NC1 and
NC2 domains when compared with the form containing
NC1, hinge and NC2 in the present study. The percen-
tage of EBA patients with autoantibodies targeting only
epitopes outside its NC1 and NC2 domains is unknown.
However, since EBA was generally previously diagnosed
by reactivity with the NC1 domain of collagen VII,
patients showing only reactivity against the hinge region
may have been largely excluded from our study. There-
fore, the immunossay described here allows characteriz-
ing the prevalence of autoantibodies against the hinge
region of collagen VII and should increase the yield of
EBA patients, which will test positive by ELISA. In addi-
tion, as suggested by previous studies [21,35], the reactiv-
ity against the hinge region of collagen VII may be
associated with inflammatory rather than mechanobul-
lous blistering disease. The new recombinant proteins
generated in this study will help clarifying this aspect in
larger cohorts of patients with disease associated with
autoimmunity against collagen VII.
Low levels of collagen VII-specific autoantibodies were
detected in a number of patients with other autoimmune
Figure 6 Autoantibodies against collagen VII are mainly of
IgG4 isotype. Box-and-whiskers graphs represent descriptive
summaries of the measurements for IgG1, IgG2, IgG3 and IgG4
autoantibodies against collagen VII by ELISA as described in
Methods.
Table 2 Sensitivity and specificity of ELISA systems for the detection of autoantibodies against collagen VII
Study Recombinant autoantigen Commercially available Sensitivity Specificity Reference
Chen et al. (n = 24) NC1 domain No 100% - [22]
Pendaries et al. (n = 41) Collagen VII full length No 68% 96% [25]
Saleh et al. (n = 49) NC1 + NC2 Yes 93.8% 98.1% [26]
Komorowski et al.(n = 73) NC1 domain Yes 91.8% 99.8% [27]
Licarete et al.
(n = 50)
NC1-hinge-NC2 - 94% 98% present study
Licarete et al. BMC Immunology 2012, 13:16
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autoimmune and inflammatory diseases the presence of
autoantibodies against collagen VII may be the result of
an epitope spreading process. Our findings are in line
with the observation that healthy blood donors and
patients without skin blisters show pemphigoid autoanti-
bodies [36-38]. The pathogenic significance of collagen
VII-specific autoantibodies in other autoimmune blister-
ing diseases and in healthy subjects is still unclear. As
shown in our present study, these autoantibodies do not
show binding to the dermal-epidermal junction by indir-
ect IF microscopy suggesting that they do not bind in
vivo. In addition, our previous in vivo studies documen-
ted that the mere presence of tissue-bound autoantibo-
dies in experimental EBA does not result in skin disease
[11].
Autoantibodies with different molecular specificity are
present in healthy individuals and in patients with var-
ious diseases (e.g., ANAs prevalence is about 3-15%).
We have found collagen VII-specific autoantibodies in
4% and 18% of patients with CD and UC, respectively.
Our present results in CD patients are in line with our
previous study showing collagen VII-specific autoantibo-
dies by immunoblotting in 5.8% of CD and 5.8% of UC
patients, in contrast to over 60% of CD patients initially
reported [23,24]. Interestingly, we measured collagen
VII-specific autoantibodies in a higher percentage of UC
patients compared with 5.8% and 12.9%, that were
reported in the previous studies [39,40]. The reason for
this discrepancy is not known and future studies in lar-
ger number of IBD patients should help defining the
prevalence of collagen VII-specific autoantibodies in
these patients. There is apparently no correlation of col-
lagen VII-specific autoantibodies with inflammation
markers in patients with CD and UC. While several
hypotheses have been advanced, the induction of auto-
immune response against collagen VII and the patho-
genic significance of specific autoantibodies in
inflammatory bowel disease is still elusive [2,41].
As with other autoantibody-induced diseases, ELISA
levels of collagen VII-specific autoantibodies likely cor-
relate with the disease severity [13,26]. It is therefore
expected that measuring the autoantibody levels, will
help predicting short-term clinical evolution in EBA
patients and guide therapeutic decisions. A more general
prognostic value of the levels of EBA autoantibodies for
the long-term disease course, including the resistance to
treatment, has not yet been addressed. Addressing this
question, which requires a more wider approach in pro-
spective clinical study, should be addressed in the future
using the tools generated this study.
Our present results strongly suggest the existence of
non-pathogenic autoimmunity against collagen VII in
patients and healthy individuals. Why autoantibodies
specific to collagen VII and XVII do not induce tissue
damage in all individuals and conditions is not known.
I n a d v e r t e n ta u t o i m m u n er e s p o n s e sm a yb eu n c o u p l e d
from disease by various mechanisms, including cryptic B
cell autoepitopes, typically seen in Goodpasture syn-
drome [39,40], anatomic, cellular and molecular barriers
that avert either tissue deposition of immune complexes
[42,43] or the engagement of inflammatory effectors by
tissue-bound antibodies [44]. In this context, the IgG
subclass is a major determinant of autoantibody patho-
genicity. Similar to a previously published report, our IgG
subclass analysis revealed a dominant IgG4 response in
patients with collagen VII-specific autoantibodies [45].
However, while the other subclasses of autoantibodies
w e r el e s sr e p r e s e n t e dw ec o u l dn o td o c u m e n tas t r i c t
restriction to IgG1 and IgG4 [45]. The mechanisms of
tissue damage in EBA may be inflammatory, requiring
the activation of complement and leukocytes by bound
autoantibodies, or non-inflammatory just involving the
binding of autoantibodies independent of their Fc por-
tions [13]. Our own results and data from the literature
show that in addition to IgG1, which shows good Fcg-
dependent complement- and leukocyte-activating capa-
city, non-complement-fixing IgG4 autoantibodies contri-
bute to tissue damage by activating the leukocytes, albeit
with a reduced efficiency compared with IgG1 [46]. In
addition, IgG4 could induce tissue damage just by bind-
ing to collagen VII in an Fc-independent manner [13].
While experimental data to support this hypothesis are
still scarce, our present findings suggest that IgG4 may
unfold its pathogenic potential in this way.
Conclusions
In conclusion, we have developed an immunoassay using
a chimeric recombinant collagen VII containing major
in silico predicted and wetlab mapped autoepitopes for
detecting autoantibodies against collagen VII. We show
a low prevalence of collagen VII-specific autoantibodies
in patients with unrelated inflammatory and autoim-
mune diseases. This immunoassay will be a useful tool
for the sensitive and specific detection of collagen auto-
antibodies in epidermolysis bullosa acquisita and other
diseases associated with autoimmunity against collagen
VII.
Additional material
Additional file 1: Table S1 Predicted antigenic epitopes of human
collagen VII.
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